Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?

被引:160
作者
Meltzer, Herbert Y. [1 ]
Sumiyoshi, Tomiki [2 ]
机构
[1] Vanderbilt Univ, Sch Med, Vanderbilt Psychiat Hosp, Dept Psychiat, Nashville, TN 37212 USA
[2] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Neuropsychiat, Toyama 9300194, Japan
关键词
Serotonin; 5-HT1A; Cognition; Dopamine; Schizophrenia;
D O I
10.1016/j.bbr.2008.05.016
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Cognitive impairment is a key feature of schizophrenia and may be the most important determinant of outcome in schizophrenia. This impairment is diffuse and may reflect abnormalities in frontal cortex, hippocampus and other brain regions. While deficits in glutamatergic, GABAergic, dopaminergic and cholinergic impairment have received the most attention as the basis of this impairment, there are many reasons for considering the role of serotonin (5-HT) in contributing to these deficits. This may be via its influence on dopaminergic, cholinergic, glutamatergic and GABAergic function, as well as various growth factors that have been implicated in schizophrenia. Of the 14 known serotonin receptors, the 5-HT1A receptor is a key candidate for mediating at least some of the influence 5-HT has on cognition. 5-HT1A receptors are upregulated in postmortem specimens from patients with schizophrenia, suggesting a deficit in 5-HT1A function in this disorder. Atypical but not typical antipsychotic drugs stimulate the efflux of dopamine from cortex by a 5-HT1A-dependent mechanism. A series of studies from this laboratory involving the 5-HT1A partial agonists tandospirone and buspirone have reported a modest ability of these agents to improve some domains of cognition in patients receiving typical or atypical antipsychotic drugs. Preclinical studies have been mixed in regard to the ability of 5-HT1A partial agonists to improve cognition in various paradigms; some studies report that 5-HT1A antagonists are effective to improve cognition. Aripiprazole, clozapine, olanzapine, perospirone, quetiapine risperidone, and ziprasidone are examples of atypical antipsychotic drugs which are either direct or indirect 5-HT1A agonists which have been shown to improve cognitive function in patients with schizophrenia. Further study is needed to determine the role of the 5-HT1A receptor to improve cognitive function in schizophrenia. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:98 / 102
页数:5
相关论文
共 65 条
  • [21] Alterations in the cortical serotonergic system in schizophrenia: A postmortem study
    Gurevich, EV
    Joyce, JN
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 42 (07) : 529 - 545
  • [22] ANALYSIS OF TANDOSPIRONE (SM-3997) INTERACTIONS WITH NEUROTRANSMITTER RECEPTOR-BINDING SITES
    HAMIK, A
    OKSENBERG, D
    FISCHETTE, C
    PEROUTKA, SJ
    [J]. BIOLOGICAL PSYCHIATRY, 1990, 28 (02) : 99 - 109
  • [23] HARVEY PD, 2007, SCHIZOPHR RES
  • [24] INCREASE IN SEROTONIN 5-HT1A RECEPTORS IN PREFRONTAL AND TEMPORAL CORTICES OF BRAINS FROM PATIENTS WITH CHRONIC-SCHIZOPHRENIA
    HASHIMOTO, T
    NISHINO, N
    NAKAI, H
    TANAKA, C
    [J]. LIFE SCIENCES, 1991, 48 (04) : 355 - 363
  • [25] Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1A receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)
    Hirst, Warren D.
    Andree, Terrance H.
    Aschmies, Suzan
    Childers, Wayne E.
    Comery, Thomas A.
    Dawson, Lee A.
    Day, Mark
    Feingold, Irene B.
    Grauer, Steven M.
    Harrison, Boyd L.
    Hughes, Zoe A.
    Kao, John
    Kelly, Michael G.
    van der Lee, Heidi
    Rosenzweig-Lipson, Sharon
    Saab, Annmarie L.
    Smith, Deborah L.
    Sullivan, Kelly
    Rizzo, Stacey J. Sukoff
    Tio, Cesario
    Zhang, Mei-Yi
    Schechter, Lee E.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 325 (01) : 134 - 145
  • [26] 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation:: a possible mechanism of atypical antipsychotic-induced cortical dopamine release
    Ichikawa, J
    Ishii, H
    Bonaccorso, S
    Fowler, WL
    O'Laughlin, IA
    Meltzer, HY
    [J]. JOURNAL OF NEUROCHEMISTRY, 2001, 76 (05) : 1521 - 1531
  • [27] Kasper Siegfried, 2002, World J Biol Psychiatry, V3, P133, DOI 10.3109/15622970209150614
  • [28] Baseline neurocognitive deficits in the CATIE schizophrenia trial
    Keefe, Richard S. E.
    Bilder, Robert M.
    Harvey, Philip D.
    Davis, Sonia M.
    Palmer, Barton W.
    Gold, James M.
    Meltzer, Herbert Y.
    Green, Michael F.
    Miller, Del D.
    Canive, Jose M.
    Adler, Lawrence W.
    Manschreck, Theo C.
    Swartz, Marvin
    Rosenheck, Robert
    Perkins, Diana O.
    Walker, Trina M.
    Stroup, T. Scott
    McEvoy, Joseph P.
    Lieberman, Jeffrey A.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2006, 31 (09) : 2033 - 2046
  • [29] The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine
    Kern, Robert S.
    Green, Michael F.
    Cornblatt, Barbara A.
    Owen, J. Randall
    McQuade, Robert D.
    Carson, William H.
    Ali, Mirza
    Marcus, Ron
    [J]. PSYCHOPHARMACOLOGY, 2006, 187 (03) : 312 - 320
  • [30] AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4] oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus
    Li, Zhu
    Bonhaus, Douglas W.
    Huang, Mei
    Prus, Adam J.
    Dai, Jin
    Meltzer, Herbert Y.
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 572 (2-3) : 129 - 137